An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

NCT02726581 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Elotuzumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]